MaxCyte Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Maher Masoud

Chief Executive Officer (CEO)

US$890.4k

Compensación total

Porcentaje del salario del CEO	50.5%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1yrs
Promedio de permanencia en la Junta Directiva	3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Maher Masoud en comparación con los beneficios de MaxCyte?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	US$890k	US$450k	-US$38m
Sep 30 2023	n/a	n/a	-US$37m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$791k	US$413k	-US$24m

Compensación vs. Mercado: La compensación total ($USD790.87K) de Maher está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD1.02M).

Compensación vs. Ingresos: La compensación de Maher ha aumentado mientras la empresa no es rentable.

CEO

Maher Masoud (48 yo)

less than a year

Permanencia

US$890,365

Compensación

Mr. Maher Masoud is President, CEO & Director of MaxCyte, Inc. since January 1, 2024 and served as its Head of Global Business Development and Legal Officer since November 2023 and had been its Secretary s...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Maher Masoud	President	less than a year	US$890.37k	sin datos
Douglas Doerfler	Founder	25.9yrs	US$3.14m	0.32% $ 1.5m
Douglas Swirsky	Chief Financial Officer	1.3yrs	US$1.29m	sin datos
Jay Gelfman	Senior Vice President of Operations	less than a year	sin datos	sin datos
Ronald Holtz	Executive Vice President of Administration	1.3yrs	US$948.33k	sin datos
David Sandoval	Senior Vice President	less than a year	sin datos	sin datos
Thomas Ross	Executive Vice President of Global Sales	9.8yrs	sin datos	sin datos
Jack Horgan	Vice President of Corporate Development	less than a year	sin datos	sin datos
Jill Mayer	Senior Vice President of Human Resources	less than a year	sin datos	sin datos
J. Thompson	Consultant	2.7yrs	US$264.50k	sin datos
James Brady	Senior VP of Technical Applications & Customer Support	2.8yrs	sin datos	sin datos
Ali Soleymannezhad	Executive VP of Bioprocessing	less than a year	sin datos	sin datos

1.0yrs

Permanencia media

64.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MYE0 no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Maher Masoud	President	less than a year	US$890.37k	sin datos
William Brooke	Independent Non-Executive Director	20.3yrs	US$177.24k	0.048% $ 219.2k
Arthur Mandell	Independent Non-Executive Director	18.1yrs	US$170.49k	0.36% $ 1.6m
Patrick Balthrop	Independent Non-Executive Director	1.6yrs	US$155.49k	0% $ 0
Richard Douglas	Independent Non-Executive Chairman of the Board	6.3yrs	US$190.49k	0.096% $ 435.7k
Stanley Erck	Independent Non-Executive Director	19.3yrs	US$162.24k	0.24% $ 1.1m
John Johnston	Independent Non-Executive Director	8.4yrs	US$160.49k	0.12% $ 525.4k
Yasir Al-Wakeel	Independent Non-Executive Director	3yrs	US$238.53k	0% $ 0
Rehka Hemrajani	Independent Non-Executive Director	3yrs	US$243.03k	0% $ 0
Marcela Maus	Member of Scientific Advisory Board	1.3yrs	sin datos	sin datos
Cenk Sumen	Member of Scientific Advisory Board	less than a year	US$897.25k	0% $ 0
Oliver Rando	Member of Scientific Advisory Board	1.3yrs	sin datos	sin datos

3.0yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de MYE0 se considera experimentada (3 años de antigüedad promedio).

MaxCyte Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

High number of new directors

High number of new directors

Key Executive recently bought €319k worth of stock

Recent updates

New major risk - Revenue and earnings growth

Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.092 loss per share (vs US$0.11 loss in 1Q 2023)

MaxCyte, Inc., Annual General Meeting, Jun 11, 2024

MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024

MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$0.37 loss per share (vs US$0.23 loss in FY 2022)

MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024

MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024

MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer

MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

MaxCyte, Inc. Provides Revenue Guidance Update for 2023

New major risk - Revenue and earnings growth

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.063 loss in 3Q 2022)

MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023

MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

New major risk - Revenue and earnings growth

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.10 loss per share (vs US$0.081 loss in 2Q 2022)

MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023

High number of new directors

MaxCyte, Inc. Provides Revenue Guidance for the Year 2023

High number of new directors

Key Executive recently bought €319k worth of stock

Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021)

MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023

MaxCyte, Inc. Appoints Patrick J. Balthrop, Sr. as Class II Director and Member of Nominating Committee and Corporate Governance Committee

MaxCyte, Inc. Provides Revenue Guidance for 2022

Third quarter 2022 earnings released: US$0.063 loss per share (vs US$0.032 loss in 3Q 2021)

MaxCyte, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Maxcyte, Inc. Revenue Guidance for 2022

Second quarter 2022 earnings released: US$0.081 loss per share (vs US$0.052 loss in 2Q 2021)

MaxCyte, Inc. to Report Q2, 2022 Results on Aug 10, 2022

MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2000 Growth Index

MaxCyte, Inc., Annual General Meeting, Jun 29, 2022

First quarter 2022 earnings released: US$0.04 loss per share (vs US$0.088 loss in 1Q 2021)

MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022

MaxCyte, Inc. to Report Q1, 2022 Results on May 09, 2022

Maxcyte, Inc. Announces CFO Changes, Effective as of April 15, 2022

MaxCyte, Inc. to Report Q4, 2021 Results on Mar 22, 2022

Maxcyte, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Independent Chairman of the Board recently bought €197k worth of stock

Founder recently sold €1.1m worth of stock

Third quarter 2021 earnings released: US$0.032 loss per share (vs US$0.037 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.052 loss per share (vs US$0.046 loss in 2Q 2020)

MaxCyte, Inc. Provides Preliminary Revenue Guidance for the Year 2021

High number of new directors

Forecast breakeven pushed back to 2023

Full year 2020 earnings released: US$0.17 loss per share (vs US$0.23 loss in FY 2019)

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad